This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of CG100649 Versus Celecoxib in Osteoarthritis Patients

This study has been completed.
Information provided by (Responsible Party):
CrystalGenomics, Inc. Identifier:
First received: April 22, 2011
Last updated: October 9, 2012
Last verified: October 2012
This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).

Condition Intervention Phase
Osteoarthritis Drug: CG100649 Drug: Celecoxib Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Multicenter, Noninferiority, Phase II Repeat Dose Study of CG100649 Versus Celecoxib in Osteoarthritis Patients

Resource links provided by NLM:

Further study details as provided by CrystalGenomics, Inc.:

Primary Outcome Measures:
  • WOMAC pain subscale [ Time Frame: Day 28 ]
    The primary endpoint will be the change in "Pain" (average WOMAC-Pain score in the index joint) at Day 28 vs. Baseline (Day 1 using the ITT population).

Secondary Outcome Measures:
  • Time course for change in WOMAC OA Index [ Time Frame: Days 14, 28, 42 ]
    Change in the sum of the WOMAC OA Index on Days 14, 28 and 42 vs. pre-dose Baseline WOMAC (repeated measures ANOVA)

  • Time course for change in WOMAC stiffness & function subscales [ Time Frame: Days 14, 28, 42 ]
    Change in subscales of WOMAC assessment (stiffness, physical function) on Days 14, 28 and 42 vs. Baseline WOMAC

  • Time course for change in WOMAC pain subscale [ Time Frame: Days 7, 14, 21, 28, 35, and 42 ]
    Change in the "Pain" subscale on Days 7, 14, 21, 28, 35 and 42 vs. pre-dose Baseline

  • Subject's Global Assessment [ Time Frame: Days 1, 14, 28, and 42 ]
    Subject's Global Assessment ("How Do You Feel?")

  • Physician's Global Assessment [ Time Frame: Days 1, 14, 28, and 42 ]
    Physician's Global Assessment

  • Withdrawals [ Time Frame: Day 28 ]
    Withdrawals due to lack of analgesic efficacy or non-compliance rates

  • Change in use of rescue medication [ Time Frame: Day 28 ]
    Change in total paracetamol used for rescue medication

Enrollment: 125
Study Start Date: April 2011
Study Completion Date: January 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CG100649 2 mg
capsule, once daily
Drug: CG100649
capsule, 2 mg, once daily for 28 days
Other Name: (None)
Experimental: CG100649 4 mg
capsule, 4 mg, once daily for 28 days
Drug: CG100649
capsule, 4 mg, once daily for 28 days
Other Name: (None)
Active Comparator: celecoxib 200 mg
capsule, once daily
Drug: Celecoxib
capsule, celecoxib 200 mg, once daily for 28 days
Other Name: Celebrex

Detailed Description:

This is a double-blind, randomized, multicenter, noninferiority, phase 2 study. Subjects will discontinue current medications (NSAID or COX-2 inhibitor) 5-14 days prior to randomization. Paracetamol (acetaminophen; ≤2 gm/day) may be used for breakthrough pain. Other NSAIDs, COX-2 inhibitors, opioids, and corticosteroids may not be used at any time during this study. Only subjects recording average WOMAC pain score of 4 to 8 on a 0-10 numerical rating scale during the washout period and meeting all other inclusion criteria will be randomized into the study.

Male and female adults, ages 20 and older, with a history of osteoarthritis (OA) of the knee or hip diagnosed by radiograph obtained within the past 20 years and with pain at least 3 months from OA can participate in this study. OA must be confirmed by radiographs and diagnosed according to American College of Rheumatology (ACR) guidelines. Subjects must qualify as ACR global functional status I, II, or III (excluding IV) and Kellgren-Lawrence grade 1, 2 or 3 (excluding grade 4).

Subjects meeting screening criteria will be randomized to receive 28 days dosing of an active dose of CG100649 or comparator (celecoxib).

Antiarthritic efficacy will be evaluated by changes in the Western Ontario and McMaster Universities (WOMAC) OA index completed on Day 1 (Baseline) and on Days 14, 28 and 42. The WOMAC pain subscale will be evaluated at screening and on Days 1, 7, 14, 21, 28, 35 and 42.

All doses will be administered orally once daily in the morning. There are 3 planned treatment arms (2 with active compound + one comparator (celecoxib) group) with n=44 per treatment arm. Total number of subjects will be 132.

Treatment A: CG100649: 2 mg/day (Days 1-28); Treatment B: CG100649: 4 mg/day (Days 1-28); Treatment C: celecoxib: 200 mg/day (Days 1-28); Active and comparator medications will have identical appearance.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females, age 20 years old and more, able and willing to provide written informed consent to participate in the study
  2. Confirmed osteoarthritis (OA) of the knee or hip by radiograph obtained within the past 20 years and diagnosed according to American College of Rheumatology (ACR) guidelines.
  3. Subject must have pain at least 3 month duration from osteoarthritis (OA)
  4. Normal blood pressure (BP) [systolic BP 90-140 mmHg, diastolic BP 50-90 mmHg] and heart rate (HR) [resting 45-90 beats per minute (bpm)]
  5. Subjects with hypertension should have stably taken ACE inhibitor, angiotensin II receptor (type AT1) antagonist, beta-blocker and/or diuretics at least 3 months at the time of screening in order to keep normal blood pressure. Subjects should not change or stop hypertension drug during the study.
  6. Clinical Chemistry must be within 2x normal limits
  7. Urinalysis must be within normal range.
  8. Prior to randomization on Day 1, the mean WOMAC pain score in the index joint must be between 4 and 8 on a 0-10 numerical rating scale.
  9. Subjects and their sexual partners must agree to use double barrier contraception during the study period and for 3 months afterwards or provide proof of surgical sterility or post-menopause more than 1 year.
  10. Subject must be able to read and understand and follow the study instructions.

Exclusion Criteria:

  1. Use of any analgesics except the study medication or paracetamol (acetaminophen) at any time during this study;
  2. Use of corticosteroids or intra-articular viscosupplementation within 3 months of screening;
  3. Use of antidepressants or anticonvulsants within 2 months of screening;
  4. Cognitive or psychiatric disorders, or daytime use of medications (alcohol, benzodiazepines, barbiturates, muscle relaxants) that could diminish compliance with study procedures;
  5. Use of anticoagulants (aspirin, warfarin, heparin) within 2 weeks of screening;
  6. Use of any medications that will affect pain perception (e.g. tranquilizers, hypnotics);
  7. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, or carbonic anhydrase inhibitors;
  8. Use of oriental medicine (herbal medicine) or glucosamine within 14 days of dose administration
  9. History of drug or alcohol abuse within one year prior to screening;
  10. Known allergy or hypersensitivity to sulfa drugs;
  11. History of congestive heart failure, ischemic heart disease, peripheral arterial disease, cerebrovascular disease or subjects who have one of these diseases;
  12. Use of chemotherapy agents or history of cancer, other than non-metastatic skin cancer that has been completely excised, within five (5) years prior to the screening visit;
  13. Subjects with gout, pseudogout, inflammatory arthritis, Paget's disease, chronic pain syndrome, fibromyalgia, or another major joint disease;
  14. Subjects requiring knee or hip arthroplasty within 2 months of screening or anticipating any need for a surgical procedure on the index joint during the study;
  15. Subjects who have had surgery on the affected joint within 6 months of screening and subjects with a prosthesis at the index joint;
  16. History of seizure disorder;
  17. Subjects with serious psychosocial co-morbidities;
  18. Subjects with gastrointestinal, renal, hepatic, or coagulant disorder within 6 months of screening;
  19. Esophageal or duodenal ulcer within 6 months of screening;
  20. History of nasal polyps, bronchospasm, and urticaria;
  21. Pregnant or breast-feeding;
  22. Subject with genetic problem of galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption (because celecoxib contains lactose)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01341405

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
CrystalGenomics, Inc.
Principal Investigator: Myung Chul Lee, MD Seoul National University Hospital
Principal Investigator: Seong-Il Bin, MD Asan Medical Center
Principal Investigator: Jong-Oh Kim, MD Ewha Womans University Mokdong Hospital
Principal Investigator: Chong Hyuk Choi, MD Gangnam Severance Hospital
Principal Investigator: Hong Chul Lim, MD Korea University Guro Hospital
  More Information

Responsible Party: CrystalGenomics, Inc. Identifier: NCT01341405     History of Changes
Other Study ID Numbers: CG100649-2-02
Study First Received: April 22, 2011
Last Updated: October 9, 2012

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on September 19, 2017